HIV prevention support for people starting PrEP
Part of Immune system & allergy, Infections, Mental health clinical trials.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have opioid dependence and be newly starting or newly adherent to opioid-use-disorder medicine (methadone or buprenorphine)
- Show mild cognitive impairment on a thinking/memory test (MoCA)
- Start PrEP within the past week and be able to show proof you were prescribed it
- Have HIV-negative status based on your PrEP prescription
- Report unsafe injection practices or unprotected sex in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps people who inject drugs start HIV prevention (PrEP) and medication for opioid use disorder (MOUD) faster. It may reduce HIV risk and improve access to treatment, while the study checks whether the “rapid access” approach works.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study tests a better way to start long-acting HIV prevention (PrEP) and buprenorphine for opioid use disorder while people are in jail, to see if it helps them stay healthy after release. If you are soon leaving jail and have opioid use disorder, you may be able to join.
This study tests an integrated phone-based health program (e-health) designed for women involved with the justice system who have opioid use disorder. It aims to help people who qualify for HIV prevention (PrEP) stay protected, especially by using simple, ongoing support through phone access.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study tests a program to help men who have sex with men start and stick with PrEP, a daily pill that prevents HIV. It aims to make PrEP easier to use and reduce HIV risk.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.